Friday, May 28, 2021
Ovarian Cancer: Updates to NCCN Guidelines
NCCN, the National Comprehensive Cancer Network, establishes and publishes guidelines to treating different cancers. In this video, OncLive specialists discuss the latest treatment guidelines. If you would like to download a pdf version of what the latest guidelines are, you can do so by following this link.
Friday, May 21, 2021
Targeting Progesterone Signaling Prevents Metastatic Ovarian Cancer
A new study suggests that blocking progesterone may prevent ovarian cancer. The study, "Targeting Progesterone Signaling Prevents Metastatic Ovarian Cancer" was released in the journal PNAS.
This study is important to women who have the BRCA-1 mutation. Women with this mutation generally produce high levels of progesterone during their menstrual cycles. Targeting these women with an anti-progesterone medication may provide these high risk women with an alternative to prophylactic breast or ovarian surgery.
To find out more about this study, follow this link.
Wednesday, May 19, 2021
Spiritual Approaches to Illness
Our spirit can lift us, bring hope and strength, especially when we are dealing with illness. Explore ways to open to spirit for wellbeing.
About this event
Dealing with illness challenges us physically, mentally, emotionally and spiritually. This impact brings about the need to draw upon our spirit to move through the questioning, More...
Tuesday, May 18, 2021
The State of Ovarian Cancer: Exploring the Landscape of Systemic Therapy
This is a wonderful in-depth look at the treatment options for OC and how it is evolving.
Tuesday, May 11, 2021
At Home Genetic Testing for Breast and Ovarian Cancer Risk
How important is it to receive genetic counseling both before and after testing for risk factors? Can women skip these counseling sessions without adding undue stress on themselves?
Friday, May 7, 2021
Novel Vaccine Harnesses Tumor Cells to Stimulate Immune Response
BioVaxys, the company that has developed a vaccine to stimulate the immune system, is seeking permission for compassionate use for women with advanced OC in Europe. Additionally, the company has approached the regulatory health agencies in the US and Europe to begin clinical trials in the upcoming months.
BVX-0918A, the vaccine, uses the patient's own cancer cells to make them more recognizable to the body's defense system. Specifically, the vaccine would make the cancer cell more visible for cancer-killing T-cells. BioVaxys is also planning to combine their vaccine with checkpoint inhibitors, another class of cancer medication, that block certain proteins from shutting down the body's immune response. Cancer cells hijack this natural function in the body and therefore hide from the immune system.
To read more about this fascinating research, follow this link.